Month: December 2020

MONROE TOWNSHIP, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (Nasdaq: OPTT), a leader in innovative and cost-effective ocean energy solutions, today announced financial results for the second quarter of fiscal year 2021 ended October 31, 2020.Recent Operational HighlightsSigned contract with Adams Communications & Engineering Technology (ACET) to evaluate a PB3 PowerBuoy® solution to support the U.S. Navy’s Naval Postgraduate School’s Sea, Land, Air, Military Research (SLAMR) Initiative.Received DeepStar® project award to study deployment and operational requirements of utilizing OPT’s PB3 PowerBuoy® to provide remotely controllable zero carbon power for deepwater subsea oil production applications.Deployed the OPT Marine Surveillance...

BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.Presentation details:Date: Monday, December 14, 2020Time: 2:40-3:00pm EDTInvestors can register for the conference HERE.Following the conference a webcast replay of the presentation will be available on the Investor section of the company’s website, www.electrocore.com.About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative...

TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (“Financial 15”) is pleased to announce it has reinstated Class A share dividends at a monthly distribution rate of $0.1257 for each post-consolidation FTN Class A share ($1.5084 annually) and declares $0.05625 for each FTN.PR.A Preferred share ($0.675 annually). The current rate for the Class A shares of $1.5084 is a post-consolidation yield of 17% based on Friday’s pre-consolidation closing price of $3.65. This is an increase in the dividend for the Class A shares from previous guidance. Distributions are payable January 8, 2021 to shareholders on record as at December 31, 2020.Since inception Class A shareholders have received a total of $20.53 per share and Preferred shareholders have received a total of $9.08 per share inclusive of this distribution,...

ALBUQUERQUE, N.M., Dec. 07, 2020 (GLOBE NEWSWIRE) — Array Technologies, Inc. (NASDAQ: ARRY) (the “Company”) today announced the closing of the previously announced secondary offering by a parent entity of the Company controlled by Oaktree Capital (the “Selling Stockholder”). The offering consisted of 36,656,250 shares of the Company’s common stock sold by the Selling Stockholder, which included 4,781,250 shares of the common stock following the exercise in full of the underwriters’ option to purchase additional shares of the Company’s common stock from the Selling Stockholder, at the public offering price of $35.00 per share. The Company did not receive any of the proceeds from the sale of shares by the Selling Stockholder. The Company’s common stock is listed on the Nasdaq Global Market under the symbol “ARRY.”Goldman Sachs...

PLEASANTON, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Drew Davies, Executive Vice President and Chief Financial Officer will present at the 13th Annual LD Micro Conference. Mr. Davies is scheduled to present on Monday, December 14th at 12:40 p.m. Eastern Time (9:40 a.m. Pacific Time).About Natus Medical IncorporatedNatus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.Additional information about Natus Medical can be found at www.natus.com.Natus Medical IncorporatedDrew DaviesExecutive...

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.About Auris MedicalAuris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention...

BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by ALX Oncology. In addition, ALX Oncology expects to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.Jefferies, Credit Suisse, and Piper Sandler are acting as joint book-running...